Data from the SENZA-PDN trial showed 10 kHz SCS yielded long-term, clinically meaningful reductions in HbA1c and weight in patients with PDN and T2D.

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to ...

Generic medications reduce the out-of-pocket (OOP) costs for common neurological conditions, apart from multiple sclerosis, ...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) stock is trading higher on Monday after the company released new preclinical ...

- The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical ...

Out-of-pocket costs continue to increase for patients who must buy commonly prescribed drugs to treat these five neurological ...

Jiangsu Alicorn Pharmaceutical Co. Ltd. has described AP2-associated protein kinase 1 (AAK1) inhibitors reported to be useful for the treatment of Alzheimer’s disease, bipolar disorder, Parkinson’s ...

Living with a chronic pain condition can make everyday tasks more challenging. For some people in Southern Utah dealing with ...

Lorna Rothery spoke to a team at Mid Yorkshire Teaching Hospital about the risk factors for and prevention of diabetic foot ...

Research shows neuropathy can be more severe and more common in Black breast cancer patients, causing doctors to dial back ...

When you think of the YMCA, you might think of working out. But the "Y's" Thriver's Club is about more than making your ...